- Home
- ELBM vs GOVX Comparison
ELBM vs GOVX Comparison
Compare ELBM & GOVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ELBM
- GOVX
- Stock Information
- Founded
- ELBM 2011
- GOVX 2001
- Country
- ELBM Canada
- GOVX United States
- Employees
- ELBM N/A
- GOVX N/A
- Industry
- ELBM Industrial Machinery/Components
- GOVX Biotechnology: Pharmaceutical Preparations
- Sector
- ELBM Miscellaneous
- GOVX Health Care
- Exchange
- ELBM Nasdaq
- GOVX Nasdaq
- Market Cap
- ELBM 19.2M
- GOVX 16.8M
- IPO Year
- ELBM N/A
- GOVX N/A
- Fundamental
- Price
- ELBM $1.11
- GOVX $0.63
- Analyst Decision
- ELBM Strong Buy
- GOVX Strong Buy
- Analyst Count
- ELBM 2
- GOVX 3
- Target Price
- ELBM $2.20
- GOVX $10.67
- AVG Volume (30 Days)
- ELBM 2.7M
- GOVX 565.5K
- Earning Date
- ELBM 11-14-2025
- GOVX 11-11-2025
- Dividend Yield
- ELBM N/A
- GOVX N/A
- EPS Growth
- ELBM N/A
- GOVX N/A
- EPS
- ELBM N/A
- GOVX N/A
- Revenue
- ELBM N/A
- GOVX $6,143,044.00
- Revenue This Year
- ELBM N/A
- GOVX N/A
- Revenue Next Year
- ELBM N/A
- GOVX N/A
- P/E Ratio
- ELBM N/A
- GOVX N/A
- Revenue Growth
- ELBM N/A
- GOVX 1943.07
- 52 Week Low
- ELBM $0.77
- GOVX $0.43
- 52 Week High
- ELBM $2.60
- GOVX $3.88
- Technical
- Relative Strength Index (RSI)
- ELBM 61.53
- GOVX 34.21
- Support Level
- ELBM $0.98
- GOVX $0.63
- Resistance Level
- ELBM $1.28
- GOVX $0.70
- Average True Range (ATR)
- ELBM 0.15
- GOVX 0.04
- MACD
- ELBM 0.02
- GOVX -0.00
- Stochastic Oscillator
- ELBM 60.78
- GOVX 8.33
About ELBM Electra Battery Materials Corporation
Electra Battery Materials Corp is building North America's fully integrated, localized, and environmentally sustainable battery materials park. Electra Battery Materials is an integral part of the North American battery supply chain, providing low-carbon, sustainable, and traceable raw materials for the region's fast growing electric vehicle industry.
About GOVX GeoVax Labs Inc.
Geovax Labs Inc is a clinical-stage biotechnology company developing human vaccines and immunotherapies against infectious diseases and solid tumor cancers using novel proprietary platforms. GeoVax's product pipeline includes ongoing human clinical trials for a next-generation COVID-19 vaccine and a gene-directed therapy against head and neck cancers. Additional research and development programs include preventive vaccines against Monkeypox (MPox), hemorrhagic fever viruses (Ebola Zaire, Ebola Sudan, Marburg, and Lassa), and Zika virus, as well as immunotherapies for multiple solid tumors. The Company's key clinical program is GEO-CM04S1, a next-generation COVID-19 vaccine.